SiBone $SIBN Stock Holdings Trimmed by Sterling Capital Management LLC

Sterling Capital Management LLC lessened its stake in shares of SiBone (NASDAQ:SIBN) by 96.7% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,498 shares of the company’s stock after selling 43,397 shares during the period. Sterling Capital Management LLC’s holdings in SiBone were worth $28,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. First Light Asset Management LLC boosted its holdings in shares of SiBone by 51.8% during the 2nd quarter. First Light Asset Management LLC now owns 8,127,985 shares of the company’s stock worth $132,649,000 after purchasing an additional 2,774,795 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of SiBone by 41.8% in the first quarter. Dimensional Fund Advisors LP now owns 618,939 shares of the company’s stock valued at $7,816,000 after purchasing an additional 182,465 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of SiBone by 101.6% in the first quarter. Renaissance Technologies LLC now owns 472,619 shares of the company’s stock valued at $5,969,000 after purchasing an additional 238,219 shares during the last quarter. Squarepoint Ops LLC increased its holdings in shares of SiBone by 40.3% in the second quarter. Squarepoint Ops LLC now owns 118,128 shares of the company’s stock valued at $1,928,000 after purchasing an additional 33,947 shares during the last quarter. Finally, Granahan Investment Management LLC lifted its position in SiBone by 97.6% during the first quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company’s stock worth $21,965,000 after buying an additional 858,942 shares in the last quarter. Hedge funds and other institutional investors own 98.11% of the company’s stock.

SiBone Stock Performance

SiBone stock opened at $24.27 on Friday. The firm has a 50 day simple moving average of $19.71 and a 200-day simple moving average of $16.56. SiBone has a 1-year low of $11.48 and a 1-year high of $25.92. The company has a debt-to-equity ratio of 0.19, a current ratio of 7.58 and a quick ratio of 7.55. The stock has a market cap of $1.09 billion, a price-to-earnings ratio of -78.29 and a beta of 0.64.

SiBone (NASDAQ:SIBN) last announced its quarterly earnings results on Monday, November 2nd. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.05. The business had revenue of $55.70 million during the quarter, compared to the consensus estimate of $55.31 million. SiBone had a negative net margin of 6.20% and a negative return on equity of 7.57%. On average, analysts expect that SiBone will post -0.34 EPS for the current year.

Analyst Ratings Changes

SIBN has been the topic of a number of recent research reports. Weiss Ratings raised SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 20th. Truist Financial raised their target price on SiBone from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, October 14th. Needham & Company LLC cut their target price on SiBone from $27.00 to $26.00 and set a “buy” rating for the company in a research note on Tuesday. UBS Group lifted their price target on SiBone from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, TD Cowen boosted their price target on shares of SiBone from $20.00 to $23.00 and gave the company a “buy” rating in a research report on Tuesday. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.00.

Insiders Place Their Bets

In related news, CEO Laura Francis sold 51,884 shares of the stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $19.46, for a total value of $1,009,662.64. Following the completion of the transaction, the chief executive officer directly owned 321,386 shares in the company, valued at approximately $6,254,171.56. This represents a 13.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Anshul Maheshwari sold 11,636 shares of the firm’s stock in a transaction on Monday, August 24th. The stock was sold at an average price of $20.11, for a total value of $233,999.96. Following the sale, the insider directly owned 223,284 shares of the company’s stock, valued at approximately $4,490,241.24. This trade represents a 4.95% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 258,371 shares of company stock valued at $5,156,716. Insiders own 4.00% of the company’s stock.

SiBone Profile

SI-BONE, Inc (NASDAQ: SIBN) is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.

Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.